News and Insights

Why Big Pharma keeps saying no to your press release – and how to change that

November 10, 2026

Getting a top global pharma company to approve a joint press release is one of the most challenging approvals to secure in life sciences marketing.

If you lead commercialization or marketing at a high-growth tech company, the frustration is familiar. You invest months securing a contract with a leading pharma organization. Your platform is actively improving operations, data infrastructure, or discovery science. Your investors want market validation, your sales pipeline needs momentum, and you want to share the partnership publicly.

Then your draft announcement enters the client’s corporate communications and legal pipeline, where it stalls for weeks before being quietly declined under a blanket policy against vendor endorsements.

Meanwhile, competitor platforms seem to announce partnerships with those exact same pharma giants.

Working with both enterprise pharma and scaling tech vendors, we find this challenge usually boils down to a fundamental mismatch in how each side views publicity and risk

The Pharma Mindset

To a scaling technology partner, announcing a prestigious collaboration is a vital commercial milestone.

To a publicly traded, multi-billion-dollar pharmaceutical enterprise, vendor agreements are rarely considered material to their business. While an announcement carries clear upside for the tech vendor, it introduces corporate liabilities for the pharma company:

• Unintended exposure of proprietary intellectual property, strategic priorities, or internal workflows.
• Unwanted regulatory scrutiny or legal exposure.
• The perception of a commercial product endorsement or vendor favoritism.

When an initiative carries minimal corporate upside and measurable regulatory risk, enterprise legal and communications teams default to self-preservation. Getting to an approval requires structuring the opportunity so their compliance concerns are resolved before the draft ever reaches a lawyer’s desk.

With that in mind, how can technology companies improve the odds of approval?

1. Build PR Terms Directly into the Contract

Attempting to negotiate publicity rights after an agreement is signed eliminates your leverage. Standardized communication commitments should be embedded directly into master service agreements (MSAs) or statements of work (SOWs).

• The Shareholder Requirement: Incorporate language reflecting the commercial expectation to periodically share validated milestones with investors and board stakeholders.
• Defined Review Windows: Require that public disclosure requests cannot be unreasonably withheld, and attach an explicit review turnaround time (such as 10 to 14 business days) so materials do not sit in a bureaucratic black hole.
• Contractual Fallbacks: Outline tiered visibility options in the agreement from day one. If corporate communications will not clear a formal co-branded release, pre-agree to an anonymized operational case study or a joint scientific presentation.

2. Request Compliance Boundaries Upfront

The most frequent misstep tech teams make is drafting a promotional release internally and submitting it cold to the client.

Instead, proactively ask the partner’s communications or compliance leads for their vendor disclosure standards before drafting a single sentence. Enterprise pharma companies have explicit boundaries. Some ban referencing specific business units or internal programs, others permit joint announcements only if executive quotes focus strictly on operational capability rather than commercial outcomes. Drafting directly within their existing rules prevents endless rounds of legal pushback.

Just as critical is having an internal champion in your corner. Corporate communications and legal rarely prioritize a cold vendor request, but they will review a draft backed directly by an internal leader advocating for the project’s success

3. Focus on Capabilities Over Compounds

Pharma legal departments become intensely cautious when external materials mention specific therapeutic assets, commercial brands, or proprietary programs.

If you separate the announcement from named products and focus on the overarching methodology, technical infrastructure, or enterprise workflow improvements, the legal threshold drops significantly. Highlight the foundational science, data rigor, and operational capability rather than the specific commercial asset tied to the work.

This same principle applies to customer quotes. Enterprise pharma will usually reject vendor endorsements celebrating a “strategic collaboration with Vendor X.” Instead, draft proposed quotes that position the pharma executive speaking about broader industry innovation, data modernization, or advancing scientific efficiency, framing your technology as the enabling backdrop rather than the headline.

4. Pivot to Symposia and Co-Presentations

A standalone corporate press release carries the highest regulatory scrutiny in the sector. Educational, policy, and industry presentation formats often face far less internal resistance.

Joint webinars, industry panels, and neutral conference sessions provide strong commercial validation without triggering corporate endorsement bans. When pharma giants share a stage, their communications teams often clear it by doing four things: keeping the agenda high-level, pre-screening all slides, signing neutral agreements, and excluding product mentions.

5. Utilize the Unannounced Enterprise Strategy

If a partner’s internal policies completely prohibit naming their organization, do not abandon the announcement.

Issue a release highlighting your deployment with a “top-tier global pharmaceutical company.” Note directly within the text that the organization remains unnamed due to confidentiality protocols, then focus the narrative on the specific operational roadblock addressed, the technology deployed, and the quantifiable value delivered.

The industry recognizes the scale of the customer, your commercial team gains an authorized case study for the pipeline, and your client avoids direct public exposure.

Great technology gets your company through the front door. Strategic compliance positioning gets you the green light from legal.